ASHLEY JOHNSON: Open Payments
NPI 1790267227 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,856 in 63 payments from 17 companies in 2025. Trend: 2023 $1,203 · 2024 $2,300 · 2025 $1,856
Food & beverage: $1,847Consulting: $9
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 33 | $1,080 |
| AstraZeneca Pharmaceuticals LP | 5 | $295 |
| Novartis Pharmaceuticals Corporation | 6 | $103 |
| PFIZER INC. | 2 | $59 |
| Amgen Inc. | 3 | $48 |
| CSL Behring | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Blueprint Medicines Corporation | 1 | $29 |
| Genentech USA, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
Products named: DUPIXENT, AIRSUPRA, WAYRILZ, AYVAKIT, XOLAIR, OCTAGAM IMMUNE GLOBULIN (HUMAN), TEZSPIRE, Hizentra.
Industry payments across NE — which companies pay providers there.
